| Serum UA quartiles, mg/dL | P 1 | P 2 | |||
---|---|---|---|---|---|---|
 | <5.4 | 5.4–6.0 | 6.1–6.8 | >6.8 | ||
Grip strength, kg * | Â | Â | Â | Â | Â | Â |
Participants (n = 586) | 152 | 144 | 145 | 145 | ― | ― |
  Model 1 3 | 41.1 (40.1–42.1) | 42.1 (41.1–43.2) | 41.8 (40.8–42.8) | 40.9 (39.9–42.0) | 0.74 | 0.07 |
  Model 2 4 | 41.2 (40.2–42.3) | 42.1 (41.0–43.1) | 41.8 (40.8–42.9) | 40.8 (39.8–41.9) | 0.55 | 0.09 |
  Model 3 5 | 41.6 (40.6–42.7) | 42.2 (41.1–43.2) | 41.8 (40.8–42.9) | 40.3 (39.2–41.3) | 0.07 | 0.04 |
  Model 4 6 | 41.6 (40.6–42.6) | 42.2 (41.2–43.2) | 41.8 (40.8–42.8) | 40.4 (39.3–41.4) | 0.09 | 0.05 |
Leg extension power, W/kg | Â | Â | Â | Â | Â | Â |
Participants (n = 355) | 92 | 90 | 85 | 88 | ― | ― |
  Model 1 | 18.1 (17.2–18.9) | 19.2 (18.3–20.0) | 18.8 (18.0–19.7) | 18.3 (17.4–19.2) | 0.84 | 0.06 |
  Model 2 | 18.0 (17.2–18.9) | 19.2 (18.4–20.1) | 18.8 (17.9–19.7) | 18.2 (17.4–19.1) | 0.95 | 0.05 |
  Model 3 | 18.3 (17.5–19.1) | 19.2 (18.4–20.1) | 18.9 (18.0–19.7) | 17.9 (17.0–18.8) | 0.43 | 0.03 |
  Model 4 | 18.3 (17.5–19.2) | 19.2 (18.4–20.1) | 18.9 (18.1–19.8) | 17.9 (17.0–18.8) | 0.40 | 0.03 |